3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Classical hematology
1
Conditions
Venous Thromboembolism
2
Neoplasms
2
Venous Thrombosis
1
Pulmonary Embolism
1
Neoplasm Metastasis
1
Interventions
venetoclax
1
trametinib
1
sargramostim
1
ruxolitinib
1
regorafenib
1
ponatinib
1
pertuzumab
1
pembrolizumab
1
palbociclib
1
olaparib
1
neratinib
1
lorlatinib
1
lenvatinib
1
idelalisib
1
fludarabine phosphate
1
fludarabine
1
enzalutamide
1
entrectinib
1
enasidenib
1
durvalumab
1
dehydroftorafur
1
darolutamide
1
dacomitinib
1
dabrafenib
1
copanlisib
1
cobimetinib
1
cabozantinib
1
cabazitaxel
1
bicalutamide
1
apixaban
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
Rosuvastatin Calcium
×
Classical hematology
×
Clear all
NCT01524653
2018-07-10
DISOLVE
University of Vermont
Phase 2
Completed
38 enrolled